TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX), Appili Therapeutics (TSX: APLI) (OTC: APLIF) Enter Third Amending Agreement

August 21, 2024 12:40:44

Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has entered into a third amending agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF), a biopharmaceutical company focused on developing innovative treatments and vaccines to combat some of the most challenging infectious diseases and potential bioterrorism threats. According to the agreement, Aditxt, through its wholly owned subsidiary Adivir Inc., will acquire all outstanding Class A common shares of Appili. The amendments in this agreement changes the Outside Date from Sept. 30, 2024, to Nov. 19, 2024; requires Appili to convene an annual and special shareholder’s meeting to consider, among other things, the Continuance as promptly as practicable; changes the deadline to convene a special shareholders’ meeting to consider the transaction; changes the deadline for Aditxt to complete the financing; and adds the completion of the Continuance as a condition to the completion of the arrangement.

To view the full press release, visit https://ibn.fm/Tj2Bn

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by the company’s CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information about the company, please visit www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is powered by IBN